Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it?

[1]  X. Deng,et al.  Natural variation of H3K27me3 modification in two Arabidopsis accessions and their hybrid. , 2016, Journal of integrative plant biology.

[2]  K. Cerosaletti,et al.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression , 2016, Science Translational Medicine.

[3]  Scott J. Tebbutt,et al.  A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes , 2016, Diabetes.

[4]  D. Faustman,et al.  Treg activation defect in type 1 diabetes: correction with TNFR2 agonism , 2016, Clinical & translational immunology.

[5]  J. Demengeot,et al.  Proinsulin multi‐peptide immunotherapy induces antigen‐specific regulatory T cells and limits autoimmunity in a humanized model , 2015, Clinical and experimental immunology.

[6]  J. Todd,et al.  Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study , 2015, BMJ Open.

[7]  Jeffrey A. Bluestone,et al.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.

[8]  James McCluskey,et al.  T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex , 2015, Nature Immunology.

[9]  S. Heck,et al.  Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry , 2015, The Journal of Immunology.

[10]  P. Raskin,et al.  Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. , 2015, The Journal of clinical investigation.

[11]  J. Todd,et al.  Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes , 2015, Diabetes.

[12]  D. Vergani,et al.  Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions. , 2015, Autoimmunity reviews.

[13]  G. Burmester,et al.  Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE , 2015, Annals of the rheumatic diseases.

[14]  D. Klatzmann,et al.  Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes , 2015, Diabetes.

[15]  Baiming Zou,et al.  Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. , 2015, The Journal of clinical investigation.

[16]  P. Bingley,et al.  Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes , 2014, Diabetes.

[17]  P. Bahadoran,et al.  Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. , 2014, JAMA dermatology.

[18]  W. Młynarski,et al.  Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. , 2014, Clinical immunology.

[19]  J. Todd,et al.  Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial , 2014, BMJ Open.

[20]  B. Stranger,et al.  Interindividual variation in human T regulatory cells , 2014, Proceedings of the National Academy of Sciences.

[21]  J. Melenhorst,et al.  Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity , 2014, Clinical Cancer Research.

[22]  Elizabeth Whalen,et al.  Multiple Autoimmune-Associated Variants Confer Decreased IL-2R Signaling in CD4+CD25hi T Cells of Type 1 Diabetic and Multiple Sclerosis Patients , 2013, PloS one.

[23]  J. Buckner,et al.  IL-2 therapy in type 1 diabetes: "Trials" and tribulations. , 2013, Clinical immunology.

[24]  T. Mandrup-Poulsen,et al.  Anti-cytokine therapies in T1D: Concepts and strategies. , 2013, Clinical immunology.

[25]  D. Klatzmann,et al.  Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. , 2013, The lancet. Diabetes & endocrinology.

[26]  A. Lares,et al.  Clinical Grade Manufacturing of Human Alloantigen‐Reactive Regulatory T Cells for Use in Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  R. Lechler,et al.  Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations , 2013, Haematologica.

[28]  M. Hjorth,et al.  Regulatory T cell phenotype and function 4 years after GAD–alum treatment in children with type 1 diabetes , 2013, Clinical and experimental immunology.

[29]  Clelia Di Serio,et al.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells , 2013, Nature Medicine.

[30]  S. Sakaguchi,et al.  Development and maintenance of regulatory T cells. , 2013, Immunity.

[31]  J. Bluestone,et al.  Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial , 2013, Diabetologia.

[32]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.

[33]  W. Młynarski,et al.  Administration of CD4+CD25highCD127− Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children , 2012, Diabetes Care.

[34]  Linda S. Wicker,et al.  Type 1 Diabetes-Associated IL2RA Variation Lowers IL-2 Signaling and Contributes to Diminished CD4+CD25+ Regulatory T Cell Function , 2012, The Journal of Immunology.

[35]  S. Glišić,et al.  Interaction between Treg Apoptosis Pathways, Treg Function and HLA Risk Evolves during Type 1 Diabetes Pathogenesis , 2012, PloS one.

[36]  Juan Pedro López,et al.  GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. , 2012, The New England journal of medicine.

[37]  B. Koeleman,et al.  Transfer of Regulatory Properties from Tolerogenic to Proinflammatory Dendritic Cells via Induced Autoreactive Regulatory T Cells , 2011, The Journal of Immunology.

[38]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[39]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[40]  E. Bonifacio,et al.  Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes , 2011, Diabetes.

[41]  A. Foussat,et al.  Isolation of functional autologous collagen-II specific IL-10 producing Tr1 cell clones from rheumatoid arthritis blood. , 2011, International immunopharmacology.

[42]  Jonathan H. Esensten,et al.  Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes , 2011, The Journal of Immunology.

[43]  S. Glišić,et al.  The Type of Responder T-Cell Has a Significant Impact in a Human In Vitro Suppression Assay , 2010, PloS one.

[44]  Q. Ouyang,et al.  Cutting Edge: Increased IL-17–Secreting T Cells in Children with New-Onset Type 1 Diabetes , 2010, The Journal of Immunology.

[45]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[46]  K. Cerosaletti,et al.  An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells , 2010, Genes and Immunity.

[47]  A. Ribas,et al.  Human Antigen-Specific Regulatory T Cells Generated by T Cell Receptor Gene Transfer , 2010, PloS one.

[48]  R. Baumgrass,et al.  Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells , 2010, Journal of Molecular Medicine.

[49]  F. Wong,et al.  IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes , 2010, Diabetologia.

[50]  Dorothea Busse,et al.  Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments , 2010, Proceedings of the National Academy of Sciences.

[51]  S. Laban,et al.  Induction of Treg by monocyte‐derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD‐L1 , 2009, European journal of immunology.

[52]  K. Cerosaletti,et al.  Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects , 2009, Diabetes.

[53]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[54]  A. Foussat,et al.  Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. , 2009, International immunopharmacology.

[55]  W. Hagopian,et al.  Genetic association of HLA DQB1 with CD4+CD25+high T-cell apoptosis in type 1 diabetes , 2009, Genes and Immunity.

[56]  S. Richardson,et al.  Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.

[57]  F. Wong,et al.  Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study , 2009, Clinical and experimental immunology.

[58]  C. Benoist,et al.  The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors , 2008, Proceedings of the National Academy of Sciences.

[59]  T. Abraham,et al.  Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 , 2008, European journal of immunology.

[60]  M. Peakman,et al.  Increased resistance to CD4+CD25hi regulatory T cell‐mediated suppression in patients with type 1 diabetes , 2008, Clinical and experimental immunology.

[61]  C. Akdis,et al.  In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposure , 2008, The Journal of experimental medicine.

[62]  J. Buckner,et al.  The Effector T Cells of Diabetic Subjects Are Resistant to Regulation via CD4+FOXP3+ Regulatory T Cells1 , 2008, The Journal of Immunology.

[63]  E. Sgouroudis,et al.  Impact of Protective IL-2 Allelic Variants on CD4+Foxp3+ Regulatory T Cell Function In Situ and Resistance to Autoimmune Diabetes in NOD Mice1 , 2008, The Journal of Immunology.

[64]  Johnny Ludvigsson,et al.  GAD treatment and insulin secretion in recent-onset type 1 diabetes. , 2008, The New England journal of medicine.

[65]  L. Wicker,et al.  The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice , 2008, Journal of Clinical Immunology.

[66]  D. Sojka,et al.  Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.

[67]  M. V. von Herrath,et al.  Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. , 2008, Clinical immunology.

[68]  C. Hsieh,et al.  A two-step process for thymic regulatory T cell development. , 2008, Immunity.

[69]  Soumitra Ghosh,et al.  Dynamic changes in CD4+ CD25+ high T cell apoptosis after the diagnosis of type 1 diabetes , 2007, Clinical and experimental immunology.

[70]  R. Barker,et al.  Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia , 2007, Blood.

[71]  R. A. Bailey,et al.  Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes , 2007, Nature Genetics.

[72]  W. Leonard,et al.  CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation , 2007, The Journal of experimental medicine.

[73]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[74]  M. Atkinson,et al.  No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes , 2007, Diabetes.

[75]  Edgar Schmitt,et al.  Epigenetic Control of the foxp3 Locus in Regulatory T Cells , 2007, PLoS biology.

[76]  W. Hagopian,et al.  At-Risk and Recent-Onset Type 1 Diabetic Subjects Have Increased Apoptosis in the CD4+CD25+high T-Cell Fraction , 2007, PloS one.

[77]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[78]  R. Andreesen,et al.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. , 2006, Blood.

[79]  A. Camarca,et al.  Gliadin-Specific Type 1 Regulatory T Cells from the Intestinal Mucosa of Treated Celiac Patients Inhibit Pathogenic T Cells , 2006, The Journal of Immunology.

[80]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[81]  H. Mcdevitt,et al.  Expansion of Functional Endogenous Antigen-Specific CD4+CD25+ Regulatory T Cells from Nonobese Diabetic Mice1 , 2005, The Journal of Immunology.

[82]  M. Atkinson,et al.  Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. , 2005, Diabetes.

[83]  P. Gottlieb,et al.  CD4+CD25high regulatory T cells in human autoimmune diabetes. , 2005, Journal of autoimmunity.

[84]  N. Robillard,et al.  Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA‐4 expression , 2004, European journal of immunology.

[85]  T. Ley,et al.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death. , 2004, Immunity.

[86]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[87]  R. Steinman,et al.  CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[88]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[89]  G. Schuler,et al.  Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris1 , 2004, The Journal of Immunology.

[90]  Peter R. Galle,et al.  Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 , 2004, The Journal of Immunology.

[91]  Mark Peakman,et al.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. , 2004, The Journal of clinical investigation.

[92]  H. Nawata,et al.  TGF-β1 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice , 2004, The Journal of Immunology.

[93]  S. Ziegler,et al.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. , 2003, The Journal of clinical investigation.

[94]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[95]  R. Tisch,et al.  Antigen-Specific Mediated Suppression of β Cell Autoimmunity by Plasmid DNA Vaccination1 , 2001, The Journal of Immunology.

[96]  R. Tisch,et al.  Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. , 1998, Diabetes.

[97]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[98]  A. Tobin,et al.  Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes–prone mice , 1996, Nature Medicine.

[99]  R. de Waal Malefyt,et al.  High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells , 1994, The Journal of experimental medicine.

[100]  J. D. de Vries,et al.  Autoreactive T cell clones specific for class I and class II HLA antigens isolated from a human chimera , 1988, The Journal of experimental medicine.

[101]  M. Battaglia,et al.  Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. , 2014, Current topics in microbiology and immunology.

[102]  D. Vignali,et al.  In vitro Treg suppression assays. , 2011, Methods in molecular biology.

[103]  L. Naldini,et al.  Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  M. Peakman,et al.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. , 2005, Diabetes.

[105]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[106]  J. Casanova,et al.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.

[107]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.